Gland B2B Business Model and Growth Strategy
Extensive & Vertically Integrated Manufacturing Capabilities
Overview
Manufacturing Footprint
23
00000
7 Facilities
Dundigal, Hyderabad
Sterile Injectables Facility (Flagship)
Liquid Vials, Lyophilizers, Ampoules,
Pre-filled syringes, Bags and
Ophthalmics
API Facility
USFDA (US),
MHRA (UK),
ANVISA
(Brazil), TGA
(Aus), BGV
(Germany)
4
Finished Formulation
Facilities
3
API Facilities
•
R&D pilot plant
Dundigal, Hyderabad
11,000 kg/year
767 million
units
&
R&D Pilot Plant
23 production lines with flexibility to
accommodate different product requirements
In process of commissioning additional
capacity
Plan to set up a new R&D building at
Pashamylaram, Hyderabad
Greater control over costs and quality and
mitigate supply chain related risks
Pashamylaram, Hyderabad
Pashamylaram,
Hyderabad
Sterile Injectables Facility
•
Liquid Vials, Lyophilizers, Ampoules and
Pre-filled syringes
Penems Facility
Vials (2 Lyophilizers), Dry Powder
USFDA (US),
GUB Munich
(Germany)
Vishakhapatnam
Oncology Facility
•
Liquid Vials, Lyophilizers
2 API Facilities
Visakhapatnam
Cumulative capacity of 11,000 kg/year
USFDA (US),
AGES
(Austria), TGA
(Australia),
ANVISA
(Brazil), DMA
(Denmark)
GLANDView entire presentation